Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · bladder-landscape@3

SRR8943024

—

679aa548-67ec-55f0-9a3e-d9fa3fbf36fe

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • OXIDATIVE_PHOSPHORYLATION+0.440
  • FATTY_ACID_METABOLISM+0.420
  • PEROXISOME+0.400
  • BILE_ACID_METABOLISM+0.360
  • PROTEIN_SECRETION+0.360
  • ADIPOGENESIS+0.350
  • CHOLESTEROL_HOMEOSTASIS+0.280
  • GLYCOLYSIS+0.260
  • REACTIVE_OXYGEN_SPECIES_PATHWAY+0.250
  • XENOBIOTIC_METABOLISM+0.240

Top 10 suppressed

  • G2M_CHECKPOINT-0.530
  • E2F_TARGETS-0.510
  • INTERFERON_GAMMA_RESPONSE-0.460
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.440
  • ALLOGRAFT_REJECTION-0.430
  • IL6_JAK_STAT3_SIGNALING-0.410
  • INTERFERON_ALPHA_RESPONSE-0.410
  • INFLAMMATORY_RESPONSE-0.320
  • MITOTIC_SPINDLE-0.290
  • ANGIOGENESIS-0.280

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR8518204
breast-umap@18
—F0.898
2C3L-01889
lung-landscapes@6
—cohortA20.872
3SRR8518189
breast-umap@18
—F0.870
4TCGA-B6-A0RO-01A-22R-A084-07
breast-umap@18
—C0.864
5TCGA-BH-A18S-01A-11R-A12D-07
breast-umap@18
—B0.860
6C3N-02153
lung-landscapes@6
—cohortA10.859
78f673a13-7f81-4685-a415-645ff6b5e2fb
colon-landscapes@1
——0.853
8MBCProject_3946_T5A_RNA
breast-umap@18
—C0.849
9SRR8518211
breast-umap@18
—C0.847
10TCGA-78-7163-01A-12R-2066-07
lung-landscapes@6
—cohortA10.844

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 22 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
OXIDATIVE_PHOSPHORYLATION0.440Remibrutinib— uncovered
FATTY_ACID_METABOLISM0.420Inavolisib— uncovered
PEROXISOME0.400Idelalisib— uncovered
BILE_ACID_METABOLISM0.360Inavolisib— uncovered
PROTEIN_SECRETION0.360Remibrutinib— uncovered
ADIPOGENESIS0.350Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.280Remibrutinib— uncovered
GLYCOLYSIS0.260Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.250Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.240Inavolisib— uncovered
MTORC1_SIGNALING0.210Inavolisib— uncovered
P53_PATHWAY0.190Idelalisib— uncovered
ANDROGEN_RESPONSE0.160Inavolisib— uncovered
HYPOXIA0.160Idelalisib— uncovered
HEME_METABOLISM0.140Temsirolimus— uncovered
PANCREAS_BETA_CELLS0.130Cobimetinib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.090Idelalisib— uncovered
ESTROGEN_RESPONSE_EARLY0.070Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.070Idelalisib— uncovered
MYC_TARGETS_V10.060Inavolisib— uncovered